Research of gemcitabine sensitivity in pancreatic cancer.

Research of gemcitabine sensitivity in pancreatic cancer. - Research of gemcitabine sensitivity in pancreatic cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000006840

Enrollment

100

Registered

2011-12-08

Start date

2011-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced pancreatic cancer

Interventions

Chemotherapy including gemcitabine.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Advanced pancreatic cancer diagnosed by EUS-FNA.

Exclusion criteria

Exclusion criteria: Advanced pancreatic cancer could not be diagnosed by EUS-FNA.

Design outcomes

Primary

Measure	Time frame
Response rate and prognosis of chmotherapy with GEM.	—

Countries

Japan

Contacts

Public ContactIchiro Yasuda

Gifu University Dept. of Gastroenterology

yasudaich@gmail.com058-230-6308

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026